Archives
-
Drug Responses in Cancer: Better In Vitro Metrics
2026-09-03
Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a framework for separating growth inhibition from cell killing, improving endpoint selection, time-course interpretation, and comparison of drug effects in vitro.
-
FBXO22 Degraders and 2-PCA Recruitment Ligand
2026-09-03
This bioRxiv preprint introduces chemical probes that both interrogate FBXO22 function and expand its use as an E3 ligase recruiter for targeted protein degradation. The study identifies a potent FBXO22 degrader, defines a minimal diamine-based self-degradation motif, and uses 2-pyridinecarboxaldehyde to recruit FBXO22 for degradation of BRD4 and CDK12.
-
Polybrene (Hexadimethrine Bromide) Guide
2026-09-02
A scenario-based guide to using Polybrene (Hexadimethrine Bromide) 10 mg/mL, SKU K2701, for more interpretable viral transduction, DNA transfection, and downstream cell viability or proliferation assays. It covers mechanism, compatibility controls, storage, optimization, data interpretation, and practical vendor-selection criteria.
-
Methyl-β-cyclodextrin: Membrane Workflow Guide
2026-09-02
Methyl-β-cyclodextrin (MβCD, SKU C6939) supports controlled membrane cholesterol extraction for experiments focused on membrane organization, fluidity, and cholesterol-sensitive signaling. It is a research reagent only; concentration, exposure time, solvent, and cell-model compatibility should be established experimentally rather than inferred as universal conditions.
-
Selective Autophagy and IRF3 Stability in Antiviral Immunity
2026-09-01
The reference study identifies CALCOCO2/NDP52-mediated selective autophagy as a virus load-dependent mechanism that removes IRF3 and limits excessive type I interferon signaling. It further shows that PSMD14/POH1 preserves IRF3 by removing K27-linked ubiquitin chains at lysine 313, revealing how ubiquitination and autophagic turnover cooperate to balance antiviral activation with immune suppression.
-
Regorafenib: From Kinase Breadth to RRM2 Biology
2026-09-01
Regorafenib (BAY 73-4506) is more than a broad multikinase inhibitor. Preclinical evidence connects its antiangiogenic and oncogenic signaling effects with RRM2 suppression and ERK/E2F3 disruption in melanoma. This article translates those findings into practical assay design, biomarker strategy, and translational decision-making.
-
Merimepodib (VX-497) for IMPDH Research
2026-08-31
Merimepodib (VX-497) connects guanine-nucleotide depletion with practical antiviral, lymphocyte, and proliferation assays. This workflow-centered guide shows how to use its selective IMPDH mechanism, guanosine rescue, and cell-model comparisons to distinguish pathway-specific effects from nonspecific toxicity.
-
5-Methyl-CTP for Robust mRNA Synthesis
2026-08-31
Learn how 5-Methyl-CTP can be integrated into in vitro transcription workflows to evaluate enhanced mRNA stability and improved mRNA translation efficiency. A practical, control-driven workflow connects nucleotide selection with vaccine-oriented mRNA drug development while separating product capabilities from evidence generated in animal studies.
-
TRIM46 Splicing Controls Axon Formation
2026-08-30
The reference study shows that TRIM46 is regulated at multiple levels during axon formation: transcription, alternative splicing, nonsense-mediated mRNA decay, and protein stability. Its key implication is that neuronal timing and tissue specificity can arise from coordinated control of RNA isoforms and protein output rather than from transcription alone.
-
Cisplatin as a Systems Biology Perturbation Tool
2026-08-29
Cisplatin, or CDDP, is more than a cytotoxic benchmark: it is a precisely interpretable perturbation for linking DNA damage, apoptosis, oxidative stress, and tissue-specific outcomes. This guide translates ovarian injury findings into stronger assay design for cancer research and mechanistic studies.
-
CHIR-99021: Decoding Stem Cell State Transitions
2026-08-28
CHIR-99021 (CT99021) is more than a Wnt activator: it is a powerful perturbation tool for separating acute GSK-3 signaling from durable stem cell fate decisions. This guide integrates product chemistry with new AGO1–HOP protein-folding insights to improve assay design and interpretation.
-
Limb Organoids Reveal How AER Cells Shape Cell Fate
2026-08-28
Skoufa and colleagues developed mouse embryonic stem cell-derived limb organoids, or budoids, containing AER-like, surface ectoderm, and mesodermal populations. The model shows that AER-like cells coordinate both local cell identity and broader tissue polarization, offering a tractable system for studying limb morphogenesis and regeneration.
-
miR-196a, MYC/TERT/NFκB in Esophageal Cancer
2026-08-27
The 2025 reference study identifies miR-196a as more than a progression marker in esophageal adenocarcinoma: it functions as a driver of epithelial-to-mesenchymal transition, motility, and aggressive signaling. Its mechanistic model connects NFKBIA loss and VCP downregulation with c-MYC accumulation, TERT activation, and reinforced NFκB signaling, providing a rationale for pathway-focused cancer research.
-
10074-G5 for Reproducible c-Myc Assays
2026-08-27
This scenario-based guide explains how 10074-G5 (SKU C5722) can support c-Myc mechanism studies, viability assays, apoptosis profiling, and cell cycle analysis. It covers solvent compatibility, dose-response design, interpretation of IC50 data, protocol controls, and practical supplier-selection criteria.
-
SAG Smoothened Receptor Agonist: Assay Guide
2026-08-26
SAG provides a controllable way to activate Smoothened downstream of Patched, making it valuable for pathway rescue, mechanistic controls, neurobiology, and developmental studies. This guide connects practical dosing and assay design with a recent study showing how SAG can distinguish ligand-level Hedgehog inhibition from Smoothened-level signaling.